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SIR,-May we, through the courtesy of
your columns, inform surgeons, radio-
therapists and other interested doctors of a
new clinical trial which will shortly be
launched?
This will be a nationwide study, supported
by the Cancer Research Campaign, in which
the main objective will be to compare two
types of treatment. Patients will be prospec-
tively randomized to undergo either simple
mastectomy with axillary node sampling and
postoperative radiotherapy, or local excision
oftumour ("lumpectomy"), also with axillary
nodes sampling and radical radiotherapy
treatment. This study protocol provides for
radiotherapy in similar dosage to both
groups of patients, so that the surgical treat-
ment will be the only variable. Although the
survival of these patients will of course be of
the greatest importance, the trial design will
also allow us to assess the local recurrence
rate, the cosmetic results of treatment, and
(in a selected group of patients) the psycho-
logical sequelae of the two methods of
treatment.
In order for this study to have the power
to discriminate between small but possibly
important differences in these two methods
of treatment, it will be necessary to include
a large number ofpatients. We hope to study
some 2000 women. We therefore invite all
interested clinicians to participate in this
trial and if you wish to receive a protocol,
please write to Mrs J. Houghton at the
address below.
Our motivation has been a genuine uncer-
tainty on the part of this Working Party as
to whether local excision with radical radio-
therapy offers a realistic and safe alternative
to mastectomy, and we feel that this study
should make a major contribution towards
answering this critical question.
M. J. PECKHAM
J. S. TOBIAS
M. BAUM
D. A. BERSTOCK
J. A. BULLIMORE
J. CUZICK
K. DURRANT
C. FAULDER
G. P. MAGuIRE
H. WHITE
J. SLOANE
C. TEASDALTE
J. HOUGHTON
Breast Conservation Working Party,
Cancer Research Campaign,
Clinical Trials Centre,
King's College Hospital Medical School,
Rayne Institute,
123 Coldharbour Lane,
London SE5 9NU
POSTCHEMOTHERAPY STAGING LAPAROTOMY IN HODGKIN'S
DISEASE
SIR.-Barr et al. (1982) recently concluded
in this journal that a postchemotherapy
staging laparotomy (SL) in Hodgkin's disease
is not recommended either for patients in
clinical remission or for patients with
evidence ofrelapsed disease, regardless ofthe
stage ofdisease.
We agree that SL is of little value for
carefully-staged patients with CS I and
II disease having been initially treated
with polychemotherapy instead of radio-
therapy.
On the other side our own experience
supports the conception that SL might be
justified furthermore in patients with CS IIIB
and IVB disease to detect residual tumor not
sufficiently eradicated by polychemotherapy
(Sutcliffe & Stansfield, 1978).
During the 10-year period 1972 to 1981
56/88 patients (64%) with stage IIIB (n=46)
or IVB (n=10) have had a postprimary
staging laparotomy (PPSL) (Kuse et al., 1979)
within 2 months after the completion of at
least 6 cycles of COPP- or COPP+ABVD-
polychemotherapy. The median age was 32
and the range, 15-60 years. In 27 cases PPSL1006 LETTERS TO THE EDITOR
was not performed on behalf of medical
reasons, refusal, or progression of disease.
Five additional patients had a positive
splenectomy before therapy.
Forty-eight out of 56 patients were con-
sidered to be in clinical remission after
chemotherapy. Nine of them (19%) showed
active disease in spleens of normal size at
laparotomy. Further polychemo- or radio-
therapy could be started early and 6/9
patients reached a long-lasting complete
remission. All 8 cases suspected for residual
disease on behalf of elevated sedimentation
rate showed active disease in normal sized
spleens (n=5) or in paraaortic lymph nodes
(n=3). Only 2 of them reached a complete
remission by further management.
Because non-invasive methods including
computerized tomography may fail in restag-
ing of Hodgkin's disease and make the
assessment of clinical remission after chemo-
therapy in stage IIIB and IVB patients
difficult, PPSL might be ofconsiderable value
and enhance the probability of long-term
survival for this former poor-risk group (Kuse
et al., 1981).
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